Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2

Biochemical and Biophysical Research Communications

Volumn 455, Issue 3-4, 2014, Pages 347-352

  Fujimoto, Mai ^a,b   Ohte, Satoshi ^a,c   Shin, Masashi ^a,d   Yoneyama, Katsumi ^a   Osawa, Kenji ^a   Miyamoto, Arei ^a   Tsukamoto, Sho ^a   Mizuta, Takato ^a   Kokabu, Shoichiro ^a,e   Machiya, Aiko ^a,b   Okuda, Akihiko ^a   Suda, Naoto ^b   Katagiri, Takenobu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d FORSYTH INSTITUTE   (United States)

^e KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Chondrocytes; Embryonic stem cells; Fibrodysplasia ossificans progressiva BMP receptor

Indexed keywords

ALK2 PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; DOXYCYCLINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR 1; ACVR1 PROTEIN, HUMAN; ACVR1 PROTEIN, MOUSE; BONE MORPHOGENETIC PROTEIN; MUTANT PROTEIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; EMBRYONIC STEM CELL; HETEROTOPIC OSSIFICATION; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; OSSIFYING MYOSITIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; CARTILAGE CELL; CHEMISTRY; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

MURINAE;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CHONDROCYTES; CHONDROGENESIS; DISEASE MODELS, ANIMAL; DOXYCYCLINE; EMBRYONIC STEM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MUTANT PROTEINS; MUTATION; MYOSITIS OSSIFICANS; SIGNAL TRANSDUCTION;

EID: 84914145319     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.11.012     Document Type: Article

References (31)

1. J.A. Kitterman, S. Kantanie, D.M. Rocke, and F.S. Kaplan Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressive Pediatrics 116 2005 654 661
2. T. Katagiri Heterotopic bone formation induced by bone morphogenetic protein signaling: fibrodysplasia ossificans progressive J. Oral Biosci. 52 2010 33 41
3. R.J. Pignolo, E.M. Shore, and F.S. Kaplan Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons Pediatr. Endocrinol. Rev. Suppl. 2 2013 437 448
4. E.M. Shore, M. Xu, G.J. Feldman, D.A. Fenstermacher, T.J. Cho, I.H. Choi, J.M. Connor, P. Delai, D.L. Glaser, M. LeMerrer, R. Morhart, J.G. Rogers, R. Smith, J.T. Triffitt, J.A. Urtizberea, M. Zasloff, M.A. Brown, and F.S. Kaplan A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressive Nat. Genet. 38 2006 525 527
5. T. Katagiri Recent topics in fibrodysplasia ossificans progressive J. Oral Biosci. 54 2012 119 123
6. T. Katagiri, and S. Tsukamoto The unique activity of bone morphogenetic proteins in bone: a critical role of the Smad signaling pathway Biol. Chem. 394 2013 703 714
7. T. Katagiri, K. Osawa, S. Tsukamoto, M. Fujimoto, A. Miyamoto, and T. Mizuta Bone morphogenetic protein-induced heterotopic bone formation: what have we learned from the history of a half century? Jpn. Dent. Sci. Rev. 2014 10.1016/j.jdsr.2014.09.004
8. T. Fukuda, M. Kohda, K. Kanomata, J. Nojima, A. Nakamura, J. Kamizono, Y. Noguchi, K. Iwakiri, T. Kondo, J. Kurose, K. Endo, T. Awakura, J. Fukushi, Y. Nakashima, T. Chiyonobu, A. Kawara, Y. Nishida, I. Wada, M. Akita, T. Komori, K. Nakayama, A. Nanba, Y. Maruki, T. Yoda, H. Tomoda, P.B. Yu, E.M. Shore, F.S. Kaplan, K. Miyazono, M. Matsuoka, K. Ikebuchi, A. Ohtake, H. Oda, E. Jimi, I. Owan, Y. Okazaki, and T. Katagiri Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressive J. Biol. Chem. 284 2008 7149 7156
9. Q. Shen, S.C. Little, M. Xu, J. Haupt, C. Ast, T. Katagiri, S. Mundlos, P. Seemann, F.S. Kaplan, M.C. Mullins, and E.M. Shore The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization J. Clin. Invest. 119 2009 3462 3472
10. S. Ohte, M. Shin, H. Sasanuma, K. Yoneyama, M. Akita, K. Ikebuchi, E. Jimi, Y. Maruki, M. Matsuoka, A. Namba, H. Tomoda, Y. Okazaki, A. Ohtake, H. Oda, I. Owan, T. Yoda, H. Furuya, J. Kamizono, H. Kitoh, Y. Nakashima, T. Susami, N. Haga, T. Komori, and T. Katagiri A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H Biochem. Biophys. Res. Commun. 407 2011 213 218
11. M. Fujimoto, S. Ohte, K. Osawa, A. Miyamoto, S. Tsukamoto, T. Mizuta, S. Kokabu, N. Suda, T. Katagiri. Mutant activin receptor-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors, Mol. Endocrinol., in press, http://dx.doi.org/10.1210/me.2014-1301.
12. E. Jimi Basic research focused on solving the clinical problems of bone metabolism regulated by transcription factor NF-κB: my personal historical narrative about the role of NF-κB in bone metabolism J. Oral Biosci. 55 2013 109 115
13. U.I. Chung, E. Schipani, A.P. McMahon, and H.M. Kronenberg Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development J. Clin. Invest. 129 2001 2977 2986
14. A.L. Culbert, S.A. Chakkalakal, E.G. Theosmy, T.A. Brennan, F.S. Kaplan, and E.M. Shore Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification Stem Cells 32 2014 1289 1300
15. S.A. Chakkalakal, D. Zhang, A.L. Culbert, M.R. Convente, R.J. Caron, A.C. Wright, A.D. Maidment, F.S. Kaplan, and E.M. Shore An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressive J. Bone Miner. Res. 27 2012 1746 1756
16. S. Masui, D. Shimosato, Y. Toyooka, R. Yagi, K. Takahashi, and H. Niwa An efficient system to establish multiple embryonic stem cell lines carrying an inducible expression unit Nucleic Acids Res. 33 2005 e43
17. T. Hishida, Y. Nozaki, Y. Nakachi, Y. Mizuno, Y. Okazaki, M. Ema, S. Takahashi, M. Nishimoto, and A. Okuda Indefinite self-renewal of ESCs through Myc/Max transcriptional complex-independent mechanisms Cell Stem Cell 1 2011 37 49
18. Y. Kato, M. Iwamoto, T. Koike, F. Suzuki, and Y. Takano Terminal differentiation and calcification in rabbit chondrocyte cultures grown in centrifuge tubes: regulation by transforming growth factor beta and serum factors Proc. Natl. Acad. Sci. U.S.A. 24 1988 9552 9556
19. J. Nojima, K. Kanomata, Y. Takada, T. Fukuda, S. Kokabu, S. Ohte, T. Takada, T. Tsukui, T.S. Yamamoto, H. Sasanuma, K. Yoneyama, N. Ueno, Y. Okazaki, R. Kamijo, T. Yoda, and T. Katagiri Dual roles of Smad proteins in the conversion from myoblasts to osteoblastic cells by bone morphogenetic proteins J. Biol. Chem. 285 2010 15577 15586
20. S. Kokabu, S. Ohte, H. Sasanuma, M. Shin, K. Yoneyama, E. Murata, K. Kanomata, J. Nojima, Y. Ono, T. Yoda, T. Fukuda, and T. Katagiri Suppression of BMP-Smad signaling axis-induced osteoblastic differentiation by small C-terminal domain phosphatase 1, a Smad phosphatase Mol. Endocrinol. 25 2011 474 481
21. T. Katagiri, M. Imada, T. Yanai, T. Suda, N. Takahashi, and R. Kamijo Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis Genes Cells 7 2002 949 960
22. G.D. Cuny, P.B. Yu, J.K. Laha, X. Xing, J.F. Liu, C.S. Lai, D.Y. Deng, C. Sachidanandan, K.D. Bloch, and R.T. Peterson Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors Bioorg. Med. Chem. Lett. 15 2008 4388 4392
23. N. Nakayama, D. Duryea, R. Manoukian, G. Chow, and C.Y. Han Macroscopic cartilage formation with embryonic stem-cell-derived mesodermal progenitor cells J. Cell Sci. 116 2003 2015 2028
24. J. Hao, J.N. Ho, J.A. Lewis, K.A. Karim, R.N. Daniels, P.R. Gentry, C.R. Hopkins, C.W. Lindsley, and C.C. Hong In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors ACS Chem. Biol. 5 2009 245 253
25. A.H. Mohedas, X. Xing, K.A. Armstrong, A.N. Bullock, G.D. Cuny, and P.B. Yu Development of an ALK2-biased BMP type I receptor kinase inhibitor ACS Chem. Biol. 8 2013 1291 1302
26. C.E. Sanvitale, G. Kerr, A. Chaikuad, M.C. Ramel, A.H. Mohedas, S. Reichert, Y. Wang, J.T. Triffitt, G.D. Cuny, P.B. Yu, C.S. Hill, and A.N. Bullock A new class of small molecule inhibitor of BMP signaling PLoS One 8 2013 e62721
27. A.H. Mohedas, Y. Wang, C.E. Sanvitale, P. Canning, S. Choi, X. Xing, A.N. Bullock, G.D. Cuny, and P.B. Yu J. Med. Chem. 9 2014 7900 7915
28. R. Yamamoto, M. Matsushita, H. Kitoh, A. Masuda, M. Ito, T. Katagiri, T. Kawai, N. Ishiguro, and K. Ohno Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice J. Bone Miner. Metab. 31 2013 26 33
29. R. Uchida, M. Nakai, S. Ohte, H. Onaka, T. Katagiri, and H. Tomoda 5-Prenyltryptophol, a new inhibitor of bone morphogenetic protein-induced alkaline phosphatase expression in myoblasts, produced by Streptomyces colinus subsp. albescens HEK608 J. Antibiot. (Tokyo) 67 2014 589 599
30. T. Fukuda, R. Uchida, S. Ohte, H. Inoue, H. Yamazaki, D. Matsuda, K. Nonaka, R. Masuma, T. Katagiri, and H. Tomoda Trichocyalides A and B, new inhibitors of alkaline phosphatase activity in bone morphogenetic protein-stimulated myoblasts, produced by Trichoderma sp. FKI-5513 J. Antibiot. (Tokyo) 65 2012 565 569
31. T. Fukuda, R. Uchida, H. Inoue, S. Ohte, H. Yamazaki, D. Matsuda, T. Katagiri, and H. Tomoda Acta Pharm. Sin. B 2 2012 23 27